Volume 3

  • No. 11 November 2022

    Combining neoadjuvant radiation and immune checkpoint therapy in HNSCC

    Combining SBRT and immune-checkpoint inhibitor durvalumab neoadjuvantly in a Phase I/Ib clinical trial in patients with HPV-unrelated HNSCC led to a high percentage of patients responding with major pathological response or complete response. Images: high-dimensional characterization of the tumor microenvironment before treatment (left two panels) and after treatment (right two panels) highlights the immune system's response to therapy.

    See Darragh et al.

  • No. 10 October 2022

    Activating complement for cancer immunotherapy

    Oncogenic EGFR signaling inhibits anti-tumor immunity via suppression of the complement system, which can be reversed to enhance immunotherapy response in non-small cell lung cancer.

    See Shao et al. See also related N&Vs by Cremer & Roumenina

  • No. 9 September 2022

    Shedding light on PARP inhibitor therapy for PDAC

    METTL16–RNA complexes sensitize pancreatic adenocarcinoma cells to inhibitors of the DNA-repair enzyme PARP1 by hindering DNA end resection.

    See Zeng et al. and the accompanying News & Views article by Perez-Pepe and Alarcón

  • No. 8 August 2022

    Immune checkpoint blockade impairs ovarian health and fertility

    Ovarian function and reserve (conceptually depicted here as an ovum surrounded by follicular cells) is impaired in mice treated with immune checkpoint inhibitors, which raises potential fertility considerations for human patients.

    See Winship et al. and the accompanying News & Views by Roberts and Dougan

  • No. 7 July 2022

    Targeting solid tumors by inducing ER stress

    Induction of endoplasmic reticulum stress through binding of a small molecule to lysosomal acid lipase A induces tumor cell death in triple-negative breast cancer without adverse effects on non-cancerous cells.

    See Liu et al.

  • No. 6 June 2022

    The expanding palette of immunotherapy

    In this issue, we launch a Series on Cancer Immunotherapy presenting commissioned Reviews and opinion pieces on the latest advances and challenges in the expanding palette of immunotherapies and their wider clinical translation, together with a selection of relevant primary research articles from Nature Cancer.

    See our June Editorial the Review article by Sanmamed et al. and the Viewpoint by Anagnostou et al.

  • No. 5 May 2022

    CDH17-directed CAR T cells for solid tumors

    CAR T cells developed to target Cadherin-17 (CDH17) eradicate neuroendocrine and gastrointestinal tumors in preclinical models, yet show no toxicity to normal tissues that also express CDH17.

    See Feng et al.

  • No. 4 April 2022

    Overcoming drug resistance in mutant EGFR lung cancer

    A mutant-selective allosteric EGFR inhibitor overcomes drug resistance in mutant EGFR lung cancer.

    See To et al.and the accompanying News & Views article by Marasco and Misale

  • No. 3 March 2022

    Cis-acting bi-specific antibodies for immunotherapy

    Bi-specific antibodies to CD40 developed to target dendritic cell subsets for cancer immunotherapy improve the therapeutic window and reduce toxicities, compared with traditional CD40 agonists.

    See Salomon et al.

  • No. 2 February 2022

    The balancing act of tissue repair and cancer

    Tissue regenerative programs triggered by radiation are orchestrated by infiltrating neutrophils and enhance metastatic growth.

    See Nolan et al.See also related News & Views article byGranot & Heinberg

  • No. 1 January 2022

    Temporal dynamics of T cells following PD-1 blockade

    Single-cell sequencing reveals temporal changes in tumor-infiltrating T cell populations before and after immune checkpoint blockade. Patients responding to treatment display accumulation of CXCL13+ precursor exhausted T cells.

    See Liu et al.